Thwaites, Ryan S. http://orcid.org/0000-0003-3052-2793
Uruchurtu, Ashley S. S. http://orcid.org/0000-0002-1979-1805
Negri, Victor Augusti
Cole, Megan E. http://orcid.org/0000-0002-5154-5786
Singh, Nehmat
Poshai, Nelisa
Jackson, David
Hoschler, Katja
Baker, Tina
Scott, Ian C.
Ros, Xavier Romero
Cohen, Emma Suzanne
Zambon, Maria http://orcid.org/0000-0002-8897-7881
Pollock, Katrina M. http://orcid.org/0000-0001-9513-5183
Hansel, Trevor T.
Openshaw, Peter J. M. http://orcid.org/0000-0002-7220-2555
Funding for this research was provided by:
RCUK | Medical Research Council
Article History
Received: 18 May 2023
Accepted: 22 November 2023
First Online: 5 December 2023
Competing interests
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: V.A.N., T.B., I.C.S., X.R-R., and E.S.C. are employees of AstraZeneca and may hold stock or stock options. AstraZeneca are the manufacturers of Fluenz Tetra/FluMist Quadrivalent intranasal influenza live virus vaccine. K.M.P. is on the data safety monitoring board for two vaccine studies (NCT05249829, NCT05575492) and has received a fee for speaking from Seqirus and Sanofi Pasteur. P.J.M.O. has received fees for scientific advisory boards from GSK, Moderna, Seqirus, Janssen and Sanofi Pasteur. The remaining authors declare no competing interests.